Evaluation by Oncologists of Strategies for the Prevention and Treatment of Chemotherapy-induced Peripheral Neuropathies
- Conditions
- Chemotherapy-induced Peripheral Neuropathy
- Interventions
- Other: survey
- Registration Number
- NCT03854864
- Lead Sponsor
- University Hospital, Clermont-Ferrand
- Brief Summary
Chemotherapy induced peripheral neuropathy (CIPN) is one of the most deleterious adverse effect of neurotoxic anticancer drugs affecting up to 40% of patients. These neurotoxic anticancer agents include mainly: cisplatin (bronchopulmonary cancers), oxaliplatin (colorectal cancers), paclitaxel (breast cancers and bronchopulmonary cancers), docetaxel (breast cancers and bronchopulmonary cancers) and bortezomib (multiple myeloma).
CIPN affects not only the quality of life of patients, it also has a major impact on oncology strategy, forcing oncologists to reduce dose-intensity, to stop an ongoing chemotherapy regimen and to change therapeutic strategies, with a risk of compromising patients' survival.
There is no real preventive or curative treatment (except duloxetine) for CIPN and it is not known what is the practice of oncologists in France? However, it is essential to know the degree of sensitivity of oncologists to this problem and their practice.
With this study, the investigators propose to assess the current practices of management by oncologists in France in 2019, for any type of practitioners of university hospital, or general hospital, for all type of neurotoxic anticancer drugs.
- Detailed Description
This observational and cross-sectional study will be conducted as a survey using the REDCap software and the response to this survey will be done online, in real time, with an automatic, secure and centralized data collection (CHU Clermont-Ferrand).
French oncologist will be contacted by email thanks to the regional cancer networks. Answer to the survey will be done online.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 216
- Oncologist
- pain physician
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Oncologists survey French oncologists
- Primary Outcome Measures
Name Time Method Treatment strategy for CIPN at day 1 Name of the drug used to treat CIPN and therapeutic adjustments, relay to a pain doctor and use of drugs)
- Secondary Outcome Measures
Name Time Method Perception of effectiveness of the treatments used at day 1 Visual analogic scale: 0 no efficacy - 100 maximal efficacy
Estimation by the oncologist of the percentage of patients affected by CIPN at day 1 Visual analogic scale: 0% - 100% of patients
Proportion of assessments of the CIPN severity performed by the oncologist using a specific questionnaire at day 1 yes / no (percentage) if yes name of the questionnaire
Proportion of CIPN assessments performed by a neurological examination (neurologist) at day 1 yes / no (percentage)
Types of neurotoxic anticancer drugs prescribed at day 1 Name of drugs
Working place at day 1 French region of practice and type of structure (public / private)
Perception of safety of the treatments used to treat CIPN at day 1 Visual analogic scale: 0 unacceptable adverse effect - 100 acceptable adverse effects
Proportion of CIPN assessments performed by the oncologist with a clinical examination at day 1 yes / no (percentage)
Age of oncologists at day 1 years
Treatment strategy for CIPN prevention at day 1 Name of the drug used to prevent CIPN and therapeutic adjustments
Number of chemotherapy prescriptions at day 1 Number of chemotherapy
Organ or system speciality of oncologists at day 1 name of speciality
Sex of oncologists at day 1 Male / female
Trial Locations
- Locations (1)
Chu Clermont-Ferrand
🇫🇷Clermont-Ferrand, France